Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial.

ABSTRACT:

Background

During percutaneous transluminal coronary angioplasty (PTCA), activated clotting time (ACT) measurements are recommended to attest a correct anticoagulation level and, if needed, to administer further unfractionated heparin (UFH) to obtain a therapeutic ACT value. Our clinical routine led us to observe that smokers had lower ACT values after standardized UFH administration during PTCA. Procoagulant status in smokers is well documented.

Objectives

To determine whether tobacco negatively affects UFH anticoagulation during PTCA when evaluated by ACT.

Methods

The ACT-TOBACCO trial is a single-center, noninterventional, prospective study. The primary end point is the comparison of ACT values after standardized UFH administration between active smokers and nonsmo

SUBMITTER: Trimole R 

PROVIDER: S-EPMC10005900 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature